Facilitating Access to Approved Medication
Get Access To Lorlatinib Tablets 25 mg
On March 3, 2021, the Food and Drug Administration granted regular approval to lorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, detected by an FDA-approved test.
- Innovator Brand Name – Ziagen
- Generic Brand Available – Abamune
- API – Lorlatinib
- Packaging – 90 Tablets
- Strength – 25 mg, 100 mg
What is Lorlatinib used for?
Lorlatinib is used to treat a certain type of lung cancer. It works by slowing or stopping the growth of cancer cells.
All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.
Get Access To Lorlatinib Tablets 25 mg
Facts of Medicines
The recommended dosage of Lorlatinib Tablets is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Swallow tablets whole. Do not chew, crush or split tablets. Do not ingest if tablets are broken, cracked, or otherwise not intact.
Take Lorlatinib Tablets at the same time each day. If a dose is missed, then take the missed dose unless the next dose is due within 4 hours. Do not take 2 doses at the same time to make up for a missed dose.
Do not take an additional dose if vomiting occurs after Lorlatinib Tablets but continue with the next scheduled dose.
Lorlatinib may cause serious side effects including: hives, difficulty breathing, swelling of your face, lips, tongue, or throat, abnormal liver function tests, chest pain, new or a worsening irregular heartbeats pattern, nausea, upper stomach pain, itching, tired feeling, loss of appetite, dark urine, clay-colored stools, and yellowing of the skin or eyes
STORAGE AND HANDLING
Lorlatinib should be stored at 20° to 25°C (68° to 77°F); excursions permitted to 15°to 30° C (59° to 86° F) [ Controlled Room Temperature]. Keep away from children.
WARNINGS AND PRECAUTIONS
Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.
Lorlatinib may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.
Patients with liver disease should be watchful and cautious in order to Lorlatinib because it can aggravate the condition.
In patients with Lorlatinib, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.
Lorlatinib is not recommended for use in infants who are under 3 months of age.
Sometimes serious hypersensitivity reactions have been associated with Lorlatinib.
FAQs – Medicine Questions
What is lorlatinib used for?
How do you take lorlatinib?
How fast does lorlatinib work?
Where can I buy lorlatinib Tablets?
You can buy lorlatinib Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.
The buyer should check the existing law in their home country before importing the product.
What is the procedure to buy lorlatinib Tablets?
Patients can simply fill the order form or can send mail at firstname.lastname@example.org. Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020 We will reply ASAP with the details of the lorlatinib Tablets price as well as procurement procedure.
Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.
Who developed Lorlatinib?
NEWS / UPDATES
- Pfizer Ltd, Electronic medicines compendium (emc), [Revised on March 2021] [ Accessed on 17th August 2021], https://www.medicines.org.uk/emc/files/pil.10632.pdf
- Pfizer, US Food and Drug Administration, [Revised on March 2021] [ Accessed on 17th August 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/210868s004lbl.pdf
- Alice T Shaw et al; First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer; The New England Journal of Medicine; Published on 19/11/2020; Accessed on 17/08/2021; https://pubmed.ncbi.nlm.nih.gov/33207094